Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
484 Leser
Artikel bewerten:
(2)

Canon Medical Informatics, Inc: Canon Medical Extends Clinically Intelligent AI-driven Enterprise Platform to include Pathology Through Partnership with Tribun Health

Finanznachrichten News

MINNETONKA, Minn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Canon Medical Informatics, Inc. has extended its Enterprise Imaging (EI) suite of solutions to include pathology through its partnership with Tribun Health. This provides new capability for healthcare organizations to efficiently include pathology into their enterprise imaging plans as part of their precision informatics roadmaps. Canon Medical offers healthcare organizations an all in one suite of solutions and one comprehensive partnership for your most imaging-intensive departments, such as radiology, cardiology, endoscopy, and now pathology.

"Our relationship with Tribun Health demonstrates our commitment to be a clinical decision partner by expanding the clinical breadth of our Enterprise Imaging solutions to drive efficiency and seamless access to critical multi-modal clinical information for all clinicians caring for patients," says Jim Litterer, President & CEO of Canon Medical Informatics. "Our future together is part of Canon Medical's overall strategy to consolidate the complex and emerging specialties that are the foundation for personalized medicine."

Delivering a common, clinically intelligent platform across complex, multi-site institutions to achieve common efficiencies for diagnosis, treatment planning and long-term patient management has been the core of Canon Medical Enterprise solutions. Serving up relevant, efficient access to imaging data optimally from its Enterprise Platform sets Canon Medical apart from solutions that segregate their departmental solutions from their VNAs. Canon Medical's EI suite combines disease-centric solutions to promote sub-specialty collaboration. Tribun Health's KLAS-leading CaloPix solution was the perfect intelligent extension with same cultural fit to Canon Medical and its solutions and services.

"Our partnership extends our reach to deliver comprehensive diagnostic and AI-based analysis to pathologists and increases the collaboration they have with their clinical partners," says Jean-Francois Pomeral, CEO of Tribun Health. "Our KLAS-leading solution coupled with Canon Medical's Enterprise Imaging solutions centrally positions the digital transformation of diagnosis with oncologists and clinicians alike."

Canon Medical solutions power some of the largest, most complex, and dynamic organizations around the world.

About Tribun Health:

Tribun Health is a leading provider of AI-powered digital pathology solutions, transforming the way pathologists diagnose and treat diseases. Our advanced technology, combined with our clinical and informatics expertise, delivers unparalleled accuracy, speed, and efficiency in pathology diagnosis.

We have been recognized as a two-time Best in KLAS award winner(2022 & 2023) for our excellence in customer satisfaction and continue to be recognized for our innovative approach to digital pathology and commitment to customer success.

Tribun Health is a pioneer in digital pathology workflow solutions with image acquisition (Macro), image storage, web-based image management system (IMS), image analysis using AI-powered deep and machine learning algorithms, remote case sharing with peer review and reporting.

Visit our website at www.tribun.healthto learn more about our end-to-end digital pathology suite.

AboutCanonMedicalInformatics, Inc.

Canon Medical Informatics, part of Canon Medical Systems, offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon.

Made for Life is a trademark of Canon Medical Systems Corporation

For more information contact:
Zach Stenger
Canon Medical Informatics, Inc.
952-487-9534
zach.stenger@mi.medical.canon
us.medical.canon/hit


© 2023 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.